<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325001/" ref="ordinalpos=87&amp;ncbi_uid=3898412&amp;link_uid=PMC3325001" image-link="/pmc/articles/PMC3325001/figure/f2-ott-5-047/" class="imagepopup">Figure 2.  From: Hedgehog <span class="highlight" style="background-color:">pathway</span> as a drug target: Smoothened inhibitors in development. </a></div><br /><div class="p4l_captionBody">Modes of Hh pathway signaling. (<b>A</b>) Type I Hh signaling is activated by specific mutations within pathway genes within tumor cells, resulting in ligand-independent constitutive activation. (<b>B</b>) Type II Hh signaling results from autocrine signaling from tumor cell to tumor cell. (<b>C</b>) Type IIIa activation results from secretion of Hh ligand by tumor cells, resulting in pathway activation in surrounding tumor stroma. (<b>D</b>) Type IIIb Hh signaling results from Hh ligand secretion by tumor stroma, resulting in activation of the pathway within tumor cells themselves.<b>Abbreviation:</b> Hh, Hedgehog.</div></div>